# DBC-664 in Adult Patients With Solid Tumors

> **NCT07705035** · PHASE1 · RECRUITING · sponsor: **Duboce Biopharmaceuticals, Inc.** · enrollment: 210 (estimated)

## Conditions studied

- Malignant Germ Cell Tumor
- Lung Adenocarcinoma
- Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma
- Urothelial Carcinoma
- Endometrial Adenocarcinoma
- Ovarian Adenocarcinoma

## Interventions

- **BIOLOGICAL:** DBC-664

## Key facts

- **NCT ID:** NCT07705035
- **Lead sponsor:** Duboce Biopharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-17
- **Primary completion:** 2030-04-01
- **Final completion:** 2030-04-01
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07705035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07705035, "DBC-664 in Adult Patients With Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07705035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*